@article{article, title  = {{A0086 – A randomised, double-blind phase II study of autogene cevumeran + nivolumab (nivo) vs. nivo as adjuvant therapy for patients with high-risk muscle-invasive urothelial carcinoma (MIUC)}},

 publisher = {{Elsevier BV}},

 url = {{https://doi.org/10.1016/j.eururo.2025.09.3293 }},

 year = {{2025}},

 month = {{3}},

 author = {{Catto JWF and Aggen D and Petros G and Loriot Y and Puente J and Sridhar SS and Ianculescu I and Vuky J and Degaonkar V and Liu LX and Yadav M et al}},

 doi = {{10.1016/j.eururo.2025.09.3293}},

 volume = {{87}},

 journal = {{European Urology}},

 pages = {{S885-S885}},

 note = {{Accessed on 2025/10/17}}}